Assessment of Adherence to Controller Inhalation Medication in Asthma- and COPD Patients.

The main aim of the study is to evaluate the adherence to controller inhalation medication in asthma and Chronic Obstructive Pulmonary Disease (COPD) in Universitair Ziekenhuis Brussel. Adherence will be assessed using the 12-question Test for the Adherence to Inhalers (TAI) yielding a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious). The aim of the study is also to compare the adherence between the 2 study subgroups (asthma and COPD patients). Several other factors which could influence the compliance of the patients will also be evaluated: age, sex, pack years, FEV1 (Forced Expiratory Volume 1), exacerbation history, symptom control, type of inhaler and number of inhalers. By identifying different patient and treatment characteristics that lead to non-adherence, future education efforts could be better targeted to these patients presenting the most important unmet need in terms of adherence.

Study Overview

• Status: Completed
• Conditions: Asthma; Adherence, Medication; COPD
• Intervention / Treatment: Other: The 12-question TAI; Other: Information from patients file; Other: The Asthma Control Test (ACT); Other: The COPD Assessment Test (CAT)

Detailed Description

Adherence to the controller inhalation medication is an important component of asthma and COPD care. Good adherence to the prescribed medication is asthma patients is associated with better symptom control and improved lung function. Also, lower exacerbation rate and mortality risk, less healthcare utilisation, lower healthcare-associated costs and a better quality of life are linked with better adherence in asthma and COPD patients.

However, studies have shown that the adherence to therapy in chronically ill patients averages around 50%. In asthma patients the level of adherence varies between 30-70%, while compliance rate in COPD patients is around 20-60% (though the numbers vary). Adherence in asthma and COPD patients is thus generally low.

Adherence in these patients is measured in studies in different ways: electronic device monitoring, dispensing data, drug levels or several self-administered questionnaires, among others. Each technique has its own benefits and drawbacks. However, the easiest to use are the self-administered questionnaires. Although many of these exist, a particularly interesting questionnaire is the TAI (Test for the Adherence to Inhalers). It exists in 2 versions: a 10-question and a longer 12-question test. The 12 question TAI has 2 added questions, in which a healthcare professional evaluates the use of the inhaler by the patient. All 12 questions can then be used to identify different non-compliance behavioural patterns. The advantages of this questionnaire are therefore that it can be used for both asthma and COPD patients, that it is designed specifically for inhalation medication and that it not only measures adherence but also the type of non-compliance .

The main aim of the study is thus to evaluate the adherence to controller inhalation medication in asthma and COPD in Universitair Ziekenhuis Brussel. Adherence will be assessed using the 12-question TAI (Test for the Adherence to Inhalers). The aim of the study is also to compare the adherence between the 2 study subgroups (asthma and COPD patients). Several other factors which could influence the compliance of the patients will also be evaluated: age, sex, pack years, FEV1, exacerbation history, symptom control, type of inhaler and number of inhalers. By identifying different patient and treatment characteristics that lead to non-adherence, future education efforts could be better targeted to these patients presenting the most important unmet need in terms of adherence.

Patient recruitment will take place at the Universitair Ziekenhuis Brussel respiratory outpatient clinic. Before their scheduled appointment, patients they will be screened to participate in the study. Recruitment will start January 2019 until March 2019, or until the target number of patients is reached. On the day of their appointment, the participants will receive all necessary information about the study and the informed consent process from the principal investigator.

Patients will have sufficient time to reflect on their participation in this study and to ask questions. After obtaining the written informed consent from the patients, the necessary interventions (filling in questionnaires and gathering information from the patients files) will take place.

It will be allowed for the patients to provide informed consent and to participate in the study on a later date.

Statistical analysis:

The statistical analysis will be conducted in 3 steps :

1. Preliminary one-way ANOVA to evaluate the dependent variable (TAI level of adherence) for each independent variable.
2. A multi-way ANOVA model will be constructed to include the relevant independent variables and potential two-way interactions, by maximization of adjusted R2 obtained through a backward elimination in order to correct for multicollinearity.
3. In a final step, the model residuals will be checked to satisfy the normality condition through application of the Kolmogorov-Smirnov and Shapiro-Wilk tests, also exploring the influence of potential heteroscedasticity.

• Study Type: Interventional
• Enrollment (Actual): 141
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Brussels
    • Brussel, Brussels, Belgium, 1090
      • Universitair Ziekenhuis Brussel

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Asthmatics with treatment ≥ GINA step 2.
• COPD-patients , GOLD stage II-IV.

Exclusion Criteria:

• No spirometry results available.
• COPD patients not on long-acting bronchodilators.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Asthmatics; From the patients file the following information will be collected by the investigators: Age; Sex; FEV1 derived from the last spirometry (including spirometry performed on day of study visit).; GINA step (Global Initiative for Asthma).; Number of exacerbations in the year prior to the study.; The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.; Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of asthma.; FENO (Fraction Exhaled Nitric Oxide) from the day of the study visit (if available). Patients will fill out: The 12-question TAI-questionnaire (test for the adherence to inhalers); The Asthma Control Test (ACT)	Other: The 12-question TAI; The 12-question TAI (Test for the Adherence to Inhalers) yields a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious).; Other: Information from patients file; Depending on which arm or group specific information will be gathered from the patients file after informed consent.; Other: The Asthma Control Test (ACT); An international validated questionnaire on the symptoms an asthmatic experiences and the disease control in the patient. Only for the Asthmatics arm of the study
Other: COPD-patients; From the patients file the following information will be collected by the investigators: Age; Sex; Pack Years; GOLD stage (Global Initiative for Chronic Obstructive Lung Disease)(post-bronchodilator FEV1); Number of exacerbations in the year prior to the study.; The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.; Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of COPD. Patients will fill out: The 12-question TAI-questionnaire (test for the adherence to inhalers); The COPD Assessment Test (CAT)	Other: The 12-question TAI; The 12-question TAI (Test for the Adherence to Inhalers) yields a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious).; Other: Information from patients file; Depending on which arm or group specific information will be gathered from the patients file after informed consent.; Other: The COPD Assessment Test (CAT); An international validated questionnaire on the symptoms a COPD-patient experiences and the disease control in the patient. Only for the COPD arm of the study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adherence to inhalation medication evaluated using the Test for the Adherence to Inhalers	Level of adherence: high (=50 points), intermediate (between 46 and 49 points) or poor (< or = 45 points) .	15 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Type of non-adherence/ Behavioural pattern (using TAI)	Sporadic non-adherence: items 1 to 5 <25points Deliberate non-adherence: items 6 to 10 < 25 points Unconscious non-adherence: items 11 and 12 < 4 points	15 minutes
Adherence in correlation to specific factors	Asthma patients: Age, sex, FEV1 derived from the last spirometry (including spirometry performed on day of study visit), GINA step, number of exacerbations in the year prior to the study, the prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day, number of different medications taken by the patient on a daily basis (excluding the inhalers for maintenance treatment of asthma), FENO from the day of the study visit (if available), result of ACT. COPD-patients: Age, sex, Pack Years, GOLD stage and GOLD group, the prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day, number of different medications taken by the patient on a daily basis (excluding the inhalers for maintenance treatment of COPD).	15 minutes

Collaborators and Investigators

• Sponsor: Universitair Ziekenhuis Brussel
• Investigators: Principal Investigator: Lisa N Vancampenhout, Master student in Medicine at Vrije Universiteit Brussel

Publications and helpful links

General Publications

• Plaza V, Fernandez-Rodriguez C, Melero C, Cosio BG, Entrenas LM, de Llano LP, Gutierrez-Pereyra F, Tarragona E, Palomino R, Lopez-Vina A; TAI Study Group. Validation of the 'Test of the Adherence to Inhalers' (TAI) for Asthma and COPD Patients. J Aerosol Med Pulm Drug Deliv. 2016 Apr;29(2):142-52. doi: 10.1089/jamp.2015.1212. Epub 2015 Jul 31.

Helpful Links

• The Asthma Control Test used in this study
• The COPD Assessment Test used in this study

Study record dates

Study Major Dates

• Study Start (Actual): January 2, 2019
• Primary Completion (Actual): April 17, 2019
• Study Completion (Actual): May 2, 2019

Study Registration Dates

• First Submitted: December 31, 2018
• First Submitted That Met QC Criteria: December 31, 2018
• First Posted (Actual): January 2, 2019

Study Record Updates

• Last Update Posted (Actual): May 29, 2019
• Last Update Submitted That Met QC Criteria: May 25, 2019
• Last Verified: May 1, 2019

More Information

Terms related to this study

• Keywords: TAI; Test for the Adherence to Inhalers
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Asthma
• Other Study ID Numbers: PNE 2018-386

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: Choice made with regards to the current General Data Protection Regulation in Europe.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No